Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma

Han, Ji‐Youn; Kim, Sun Hye; Lee, Yeon-Su; Lee, Seung Youn; Hwang, Jung-Ah; Kim, Jin Young; Yoon, Sung Jin; Lee, Geon Kook

doi:10.1016/j.lungcan.2014.04.009

Cited by 46 publications

(35 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore skin rash cannot be used as an early "biomarker" in this setting. Recently developed test, for example "fluid phase biopsy" and "targeted nextgeneration" sequencing could provide new options to predict response during EGFR-TKI therapy [21,22].…”

Section: Resultsmentioning

confidence: 99%

Skin rash in patients treated with neoadjuvant erlotinib (Tarceva) in resectable non-small cell lung cancer: Predictor for tumor response and survival?

MH¹,

Ja²,

Sikorska³

et al. 2017

J Cancer Res Ther.

View full text Add to dashboard Cite

Background: Skin rash during treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) has been reported to be predictive for response and survival in patients with advanced non-small cell lung cancer (NSCLC). The aim of this analysis was to evaluate whether skin rash during treatment (as a biomarker) in a preoperative setting was related to response and survival. Methods: This study was designed as an open-label phase II trial (also known as M06NEL). Patients received preoperative erlotinib (Tarceva) 150 mg once daily for 3 weeks. Skin toxicity during treatment was analysed in relation to metabolic and histopathological response, overall survival (OS) and progression-free survival (PFS). Results: In total 59 patients (25 male, 34 female) were eligible for analysis. In 39 patients (66%) skin toxicity occurred. According to National Cancer Institute Common Toxicity Criteria (NCICTC), Grade 1 toxicity was seen in 15 patients (25%), Grade 2 in 19 patients (32%) and Grade 3 in five patients (8%). None of the patients showed skin toxicity Grade 4 and 5. The median follow up was 74 months. Thirty-six patients (61%) were alive at time of analysis. Twenty-seven patients (46%) showed disease progression during follow up. Hazard ratios (HR) indicated lower risk of death (HR = 0.66, 95%CI: 0.29 -1.50) and progression (HR = 0.64, 0.30 -1.36), although in this small group results were not significant. Skin rash did not adequately predict response. Conclusions: In this neoadjuvant setting with limited treatment time in patients with early stage NSCLC, skin rash was not associated with response and survival and cannot be used as an early biomarker.

show abstract

Section: Resultsmentioning

confidence: 99%

Skin rash in patients treated with neoadjuvant erlotinib (Tarceva) in resectable non-small cell lung cancer: Predictor for tumor response and survival?

MH¹,

Ja²,

Sikorska³

et al. 2017

J Cancer Res Ther.

View full text Add to dashboard Cite

show abstract

“…27,28 Analysis of EGFR mutations has become an important tool for targeted therapy in lung cancer, and recently, many efforts have been made to find a more specific and sensitive method (including ARMS and NGS) to detect them. 29,30 When compared with conventional DNA direct sequencing, targeted NGS provides a more accurate and clinically useful molecular classification method for lung adenocarcinoma. 30 However, these techniques are relatively expensive for routine use in clinical laboratories, and they depend on the quality of the samples.…”

Section: Discussionmentioning

confidence: 99%

“…29,30 When compared with conventional DNA direct sequencing, targeted NGS provides a more accurate and clinically useful molecular classification method for lung adenocarcinoma. 30 However, these techniques are relatively expensive for routine use in clinical laboratories, and they depend on the quality of the samples.…”

Section: Discussionmentioning

confidence: 99%

Quantum dots immunofluorescence histochemical detection of EGFR gene mutations in the non-small cell lung cancers using mutation-specific antibodies

Qu¹,

Zhang²,

Pan

et al. 2014

IJN

View full text Add to dashboard Cite

Background Epidermal growth factor receptor (EGFR) mutation status plays an important role in therapeutic decision making for non-small cell lung cancer (NSCLC) patients. Since EGFR mutation-specific antibodies (E746-A750del and L858R) have been developed, EGFR mutation detection by immunohistochemistry (IHC) is a suitable screening test. On this basis, we want to establish a new screening test, quantum dots immunofluorescence histochemistry (QDs-IHC), to assess EGFR gene mutation in NSCLC tissues, and we compared it to traditional IHC and amplification refractory mutation system (ARMS). Materials and methods EGFR gene mutations were detected by QDs-IHC, IHC, and ADx-ARMS in 65 cases of NSCLC composed of 55 formalin-fixed, paraffin-embedded specimens and ten pleural effusion cell blocks, including 13 squamous cell carcinomas, two adenosquamous carcinomas, and 50 adenocarcinomas. Results Positive rates of EGFR gene mutations detected by QDs-IHC, IHC, and ADx-ARMS were 40.0%, 36.9%, and 46.2%, respectively, in 65 cases of NSCLC patients. The sensitivity of QDs-IHC when detecting EGFR mutations, as compared to ADx-ARMS, was 86.7% (26/30); the specificity for both antibodies was 100.0% (26/26). IHC sensitivity was 80.0% (24/30) and the specificity was 92.31% (24/26). When detecting EGFR mutations, QDs-IHC and ADx-ARMS had perfect consistency ( κ =0.882; P <0.01). Excellent agreement was observed between IHC and ADx-ARMS when detecting EGFR mutations ( κ =0.826; P <0.01). Conclusion QDs-IHC is a simple and standardized method to detect EGFR mutations with its high sensitivity and specificity, as compared with real-time polymerase chain reaction. In addition, the development of specific antibodies against EGFR mutation proteins might be useful for the diagnosis and treatment of lung cancer.

show abstract

“…In addition to EGFR alterations, this technology allows concurrent identification of other prognostic or predictive genetic alterations 38,39 . NGS has a much higher sensitivity than Sanger sequencing, 40 …”

Section: Polymerase Chain Reaction (Pcr)-based Methodsmentioning

confidence: 99%

EGFR Testing in Advanced Non–Small-Cell Lung Cancer, A Mini-Review

Sheikine

Rangachari

McDonald

et al. 2016

Clinical Lung Cancer

View full text Add to dashboard Cite

Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma

Cited by 46 publications

References 34 publications

Skin rash in patients treated with neoadjuvant erlotinib (Tarceva) in resectable non-small cell lung cancer: Predictor for tumor response and survival?

Skin rash in patients treated with neoadjuvant erlotinib (Tarceva) in resectable non-small cell lung cancer: Predictor for tumor response and survival?

Quantum dots immunofluorescence histochemical detection of EGFR gene mutations in the non-small cell lung cancers using mutation-specific antibodies

EGFR Testing in Advanced Non–Small-Cell Lung Cancer, A Mini-Review

Contact Info

Product

Resources

About

Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma

Cited by 46 publications

References 34 publications

Skin rash in patients treated with neoadjuvant erlotinib (Tarceva) in resectable non-small cell lung cancer: Predictor for tumor response and survival?

Skin rash in patients treated with neoadjuvant erlotinib (Tarceva) in resectable non-small cell lung cancer: Predictor for tumor response and survival?

Quantum dots immunofluorescence histochemical detection of EGFR gene mutations in&nbsp;the&nbsp;non-small cell lung cancers using&nbsp;mutation-specific&nbsp;antibodies

EGFR Testing in Advanced Non–Small-Cell Lung Cancer, A Mini-Review

Contact Info

Product

Resources

About

Quantum dots immunofluorescence histochemical detection of EGFR gene mutations in the non-small cell lung cancers using mutation-specific antibodies